Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome - PubMed (original) (raw)
. 1998 Oct;4(10):2383-90.
J L Formento, C Lebrun-Frenay, J Gioanni, M Chatel, P Paquis, C Bernard, A Courdi, R J Bensadoun, J P Pignol, M Francoual, P Grellier, M Frenay, G Milano
Affiliations
- PMID: 9796969
Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome
M C Etienne et al. Clin Cancer Res. 1998 Oct.
Abstract
The aim of this study was to perform a multivariate analysis including clinical and biological prognostic factors on glial tumor outcome. Seventy-nine patients were analyzed (48 men and 31 women; mean age = 56 years, range = 16-77 years): 7 had a benign glial tumor (grades 1 and 2), 21 had an anaplastic glial tumor (grade 3), and 51 had a glioblastoma (grade 4). Median follow-up was 17.9 months for patients who survived (50 patients died). Biopsies were obtained at time of diagnosis (complete tumor resection in 62 patients and stereotaxic biopsies in 17 patients). Epidermal growth factor receptor (EGFR) was measured by a binding assay, and labeling index (LI) was measured by tritiated thymidine incorporation. EGFR varied from 4 to 73,110 fmol/mg protein (mean = 3912 fmol/mg protein; median = 374 fmol/mg protein; n = 79). LI varied between 0.1 and 16.5% (mean = 6.2%; median = 5.2%; n = 40). Log10 EGFR was significantly and positively correlated with patient age. LI was significantly different according to tumor histology. Univariate Cox analysis (end point was cancer death) showed that age (P = 0.027), log10 EGFR (P = 0.025), and LI (P = 0.0019) were significant continuous variables, the survival being shortened when the covariable increased; tumor resection (P = 0.015, relative risk = 0.45) and histology (P = 0.0009) were significant categorical factors. A multivariate Cox analysis (forward selection) including age, histology, tumor resection, log10 EGFR, and LI revealed that log10 EGFR, LI, and tumor resection were the only independent significant predictors of survival. This multivariate approach reveals that the clinical prognostic factors of glial tumors, namely age and tumor histology, disappear, to the benefit of intrinsic characteristics of the tumor, i.e., EGFR expression and LI, suggesting that coupled EGFR and LI determination could be a useful tool for better evaluation of glial tumor outcome.
Similar articles
- Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Heimberger AB, et al. Clin Cancer Res. 2005 Feb 15;11(4):1462-6. doi: 10.1158/1078-0432.CCR-04-1737. Clin Cancer Res. 2005. PMID: 15746047 - A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G. Etienne MC, et al. Br J Cancer. 1999 Apr;79(11-12):1864-9. doi: 10.1038/sj.bjc.6690297. Br J Cancer. 1999. PMID: 10206306 Free PMC article. - Clinical significance of biological differences between cavitated and solid form of squamous cell lung cancer.
Gasinska A, Kolodziejski L, Niemiec J, Dyczek S. Gasinska A, et al. Lung Cancer. 2005 Aug;49(2):171-9. doi: 10.1016/j.lungcan.2005.01.007. Epub 2005 Mar 17. Lung Cancer. 2005. PMID: 16022910 - Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M. Dehais C, et al. Cancer. 2006 Oct 15;107(8):1891-7. doi: 10.1002/cncr.22211. Cancer. 2006. PMID: 16986124 - Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.
Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Psyrri A, et al. Clin Cancer Res. 2005 Aug 15;11(16):5856-62. doi: 10.1158/1078-0432.CCR-05-0420. Clin Cancer Res. 2005. PMID: 16115926
Cited by
- Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.
Sun X, Liu X, Xia M, Shao Y, Zhang XD. Sun X, et al. J Transl Med. 2019 May 16;17(1):159. doi: 10.1186/s12967-019-1908-1. J Transl Med. 2019. PMID: 31097021 Free PMC article. - Prognostic significance of epidermal growth factor receptor expression in glioma patients.
Li J, Liang R, Song C, Xiang Y, Liu Y. Li J, et al. Onco Targets Ther. 2018 Feb 7;11:731-742. doi: 10.2147/OTT.S155160. eCollection 2018. Onco Targets Ther. 2018. PMID: 29445288 Free PMC article. - Novel vaccines for glioblastoma: clinical update and perspective.
Winograd EK, Ciesielski MJ, Fenstermaker RA. Winograd EK, et al. Immunotherapy. 2016 Nov;8(11):1293-1308. doi: 10.2217/imt-2016-0059. Immunotherapy. 2016. PMID: 27993092 Free PMC article. Review. - Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Alshami J, et al. Oncotarget. 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297. Oncotarget. 2015. PMID: 26423602 Free PMC article. - Prognostic Value of MRS Metabolites in Postoperative Irradiated High Grade Gliomas.
Tolia M, Verganelakis D, Tsoukalas N, Kyrgias G, Papathanasiou M, Mosa E, Kokakis I, Kouvaris JR, Pissakas G, Pistevou-Gombaki K, Kelekis N, Kouloulias V. Tolia M, et al. Biomed Res Int. 2015;2015:341042. doi: 10.1155/2015/341042. Epub 2015 Aug 3. Biomed Res Int. 2015. PMID: 26339606 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous